Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system. Long-term follow-up of a randomised control trial

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 452-456

  Gardner, Francis J E ^a   Konje, Justin C ^b   Bell, Stephen C ^b   Abrams, Keith R ^b   Brown, Laurence J R ^c   Taylor, David J ^b   Habiba, Marwan ^b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Endometrial polyps; Endometrium; Levonorgestrel; LNG IUS; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; LEVONORGESTREL; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECIDUALIZATION; DRUG DELIVERY SYSTEM; ENDOMETRIAL THICKNESS; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH SURVEY; HUMAN; HYSTEROSCOPY; MAMMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THICKNESS; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES; LEVONORGESTREL; POLYPS; POSTMENOPAUSE; TAMOXIFEN; UTERINE DISEASES;

EID: 67651174272     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.014     Document Type: Article

References (36)

1. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
2. Goetz M.P., Suman V.J., Couch F.J., Ames M.M., Rae J.M., Erlander M.G., et al. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 14 18 (2008) 5864-5868
3. Ismail S.M. Pathology of endometrium treated with tamoxifen. J Clin Pathol 47 9 (1994) 827-833
4. Cohen I., Bernheim J., Azaria R., Tepper R., Sharony R., and Beyth Y. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 75 1 (1999) 136-141
5. Deligdisch L., Kalir T., Cohen C.J., de Latour M., Le Bouedec G., and Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 78 2 (2000) 181-186
6. Ramondetta L.M., Sherwood J.B., Dunton C.J., and Palazzo J.P. Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol 180 2 Pt 1 (1999) 340-341
7. Schlesinger C., Kamoi S., Ascher S.M., Kendell M., Lage J.M., and Silverberg S.G. Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups. Int J Gynecol Pathol 17 4 (1998) 302-311
8. Berliere M., Charles A., Galant C., and Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 91 1 (1998) 40-44
9. Vosse M., Renard F., Coibion M., Neven P., Nogaret J.M., and Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 101 1 (2002) 58-63
10. Ciatto S., Cecchini S., Gervasi G., Landini A., Zappa M., and Crocetti E. Surveillance for endometrial cancer with transvaginal ultrasonography of breast cancer patients under tamoxifen treatment. Br J Cancer 88 8 (2003) 1175-1179
11. Gardner F.J., Konje J.C., Abrams K.R., Brown L.J., Khanna S., Al-Azzawi F., et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 356 9243 (2000) 1711-1717
12. Backman T., Rauramo I., Jaakkola K., Inki P., Vaahtera K., Launonen A., et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106 4 (2005) 813-817
13. Trinh X.B., Tjalma W.A., Makar A.P., Buytaert G., Weyler J., and van Dam P.A. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 90 1 (2008) 17-22
14. Neven P., Amant F., Poppe W., and Van den Broecke R. Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer. Fertil Steril 91 4 (2009) e5 author reply e6
15. Kung F.T., and Chang S.Y. The relationship between ultrasonic volume and actual weight of pathologic uterus. Gynecol Obstet Invest 42 1 (1996) 35-38
16. Patel R.R., Sharma C.G., and Jordan V.C. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 14 2 (2007) 113-122
17. Neven P., Paridaens R., Amant F., Wildiers H., Berteloot P., Leunen K., et al. Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view. Int J Gynecol Cancer 16 Suppl. 2 (2006) 505-510
18. Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 15 1 (2008) 73-90
19. Rabaglio M., Aebi S., and Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 8 10 (2007) 940-949
20. Higgins M.J., and Davidson N.E. What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. Curr Oncol Rep 11 1 (2009) 45-50
21. Chan S.S., Tam W.H., Yeo W., Yu M.M., Ng D.P., Wong A.W., et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 114 12 (2007) 1510-1515
22. Kesim M.D., Aydin Y., Atis A., and Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 11 3 (2008) 252-257
23. Powles T.J., Bourne T., Athanasiou S., Chang J., Grubock K., Ashley S., et al. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer 78 2 (1998) 272-275
24. Panchal R., Bell S.C., Konje J.C., Brown L., and Habiba M.A. Uterine effects of levonorgestrel-impregnated intrauterine device (LNG-IUS) inserted at the onset of tamoxifen treatment in post-menopausal women with breast cancer. BJOG Int J Obstet Gynaecol 114 8 (2007) 1041
25. Goldstein S.R., Nachtigall M., Snyder J.R., and Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 163 1 Pt 1 (1990) 119-123
26. Cecchini S., Ciatto S., Bonardi R., Grazzini G., and Mazzota A. Endometrial ultrasonography - an alternative to invasive assessment in women with postmenopausal vaginal bleeding. Tumori 82 1 (1996) 38-39
27. Barakat R.R., Gilewski T.A., Almadrones L., Saigo P.E., Venkatraman E., Hudis C., et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 18 20 (2000) 3459-3463
28. Neven P., De Muylder X., Van Belle Y., Van Hooff I., and Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 351 9095 (1998) 36
29. Garuti G., Grossi F., Centinaio G., Sita G., Nalli G., and Luerti M. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. Eur J Obstet Gynecol Reprod Biol 132 1 (2007) 101-106
30. Duffy S., Jackson T.L., Lansdown M., Philips K., Wells M., Pollard S., et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. Hum Reprod 20 1 (2005) 294-301
31. Goncalves M.A., Goncalves W.J., Matias M.M., Nazario A.C., de Lima G.R., and Baracat E.C. Hysteroscopic evaluation of the endometrium of post-menopausal patients with breast cancer before and after tamoxifen use. Int J Gynaecol Obstet 66 3 (1999) 273-279
32. Willen R., Lindahl B., Andolf E., Ingvar C., Liedman R., and Ranstam J. Histopathologic findings in thickened endometria, as measured by ultrasound in asymptomatic, postmenopausal breast cancer patients on various adjuvant treatment including tamoxifen. Anticancer Res 18 1B (1998) 667-676
33. Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P.J., and Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81 5 (Pt 1) (1993) 660-664
34. Seoud M., Shamseddine A., Khalil A., Salem Z., Saghir N., Bikhazi K., et al. Tamoxifen and endometrial pathologies: a prospective study. Gynecol Oncol 75 1 (1999) 15-19
35. Gerber B., Krause A., Muller H., Reimer T., Kulz T., Makovitzky J., et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 18 20 (2000) 3464-3470
36. Fung M.F., Reid A., Faught W., Le T., Chenier C., Verma S., et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 91 1 (2003) 154-159